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was adsorbed by mesoporous silica to transfer the liquid into solid powder, ie. the 48 tacrolimus sustained release silica-lipid hybrid (SLH). The SLH was characterized by
Preparation of tacrolimus loaded LBDDS and SLH

138
Tacrolimus loaded SLH was prepared in a process of two-steps, ie., preparation of 139 drug-loaded LBDDS and the solidification of LBDDS to form the drug-loaded SLH as 140 described below. (1) Tacrolimus, and/or Compritol 888 ATO and Gelucire 50/13 were 141 accurately weighed according to the formulations listed in Table 1 , and placed into a glass 142 round bottom flask and heated at 80°C with constant stirring until all the excipients were 143 melted; then tacrolimus was added into the molten mixture at 70°C with stirring to form a 
Scanning electron microscopy (SEM) observation
153
The mesoporous silica, drug-loaded SLH and drug-loaded SLH after in vitro drug 154 release were spattered with gold, their morphologies were observed using a S-3400 SEM
155
(Hitachi, Japan) at 5.0 KV electron acceleration voltage. 
X-ray powder diffraction (XRPD)
169
The crystalline characteristics of tacrolimus, drug-loaded LBDDS, mesoporous silica 170 and drug-loaded SLH were determined by XRD-6000 X-ray Powder Diffractometry
171
(Shimadzu, Japan) at 40kV and 40mA using Cu Kα radiation. The samples were measured in 172 the 2θ range between 5° and 60° at a scan rate of 2.8° per second with step of 0.0167°. The physical state of tacrolimus, drug-loaded LBDDS, mesoporous silica and 177 drug-loaded SLH were measured with DSC-6 (Mettler-Toledo, Switzerland). Samples (about 178 5 mg) were weighed accurately and sealed in an aluminum pan and the DSC curves were 179 determined at a heating rate of 10°C/min from 25°C to 180°C under N 2 gas purge of 40 180 ml/min, and an empty pan was used as reference. The in vitro release test was performed using the paddle method described in Chinese Two methods were used to evaluate the flowability of the powders, ie. Carr's index and
219
Hausner ratio, and the tilt method.
220
The Carr's index and Hausner ratio could be calculated by Eq.1 and Eq.2, respectively
221
[32]
222
Carr's index = (tapped density -bulk density)/tapped density (Eq. 1)
Hausner ratio = tapped density/bulk density (Eq. 2)
224
And to measure the angle of repose, the cylindrical container with powder samples 225 which took up about 1/3 of the container volume was fluctuated, after the powder remained 226 repose, the angle formed by the surface of the powder was defined as the angle of repose. into the drug distribution inside the mesoporous silica particles (Fig.1,D) . Green cost/profit ratio, and environmental friendly, and by varying the ratio of the two lipids, it will 297 be easy to adjust the melting points and drug release rate. (Fig.3, C) . The similarity factor f 2 of the two release curves was calculated 311 by Eq.4, Powder densities, including true density, bulk density and tap density, of mesoporous 378 silica, SLH, and LBDDS were listed in Table 3 . It could be seen that mesoporous silica 379 had the most significant difference between the bulk density and the tap density to the 380 true density, followed by SLH and LBDDS powders. 
